If a GLP-1 is prescribed for another eligible medical condition, it will be covered according to the Part D plans rules
For people without pre-existing heart conditions, investing in these therapies still proves economically viable according to cardiovascular outcome trialsas shown by their favorable quality-adjusted life year (QALY) figureswhich underscores the broader value of GLP-1 agonists in improving cardiovascular outcomes
BPC-157 (5 mg Vial): Advanced / Aggressive Approach (1 mL = 5 mg/mL) Reconstitute: Add 1.0 mL bacteriostatic water to the BPC-157 (5 mg) vial 5 mg/mL (5,000 mcg/mL)
Per the TrumpRx site, it is expected to launch in January 2026
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ]
Put ice packs around the carton but not in direct contact with the pen surface, as direct contact can freeze and damage the medication